Page 5099: in the Introduction, the data cutoff date of the final analyses from the ALCANZA study should be 28 September 2018, not 2019.
Page 5100: in Table 1, the footnote symbol † next to “Median PFS per IRF, months (95% CI)” should be next to “64.4 (50.7-75.2)” under “Brentuximab vedotin (n = 64).” The corrected Table 1 is shown below:
Summary of efficacy (ITT population)
| . | Brentuximab vedotin (n = 64) . | Physician’s choice (n = 64) . | P . |
|---|---|---|---|
| ORR4 per IRF, n (%) | 35 (54.7)∗ | 8 (12.5) | < .001 |
| Best response per IRF, n (%) | |||
| ORR (CR + PR) | 42 (65.6) | 13 (20.3) | < .001 |
| CR | 11 (17.2) | 1 (1.6) | .002 |
| PR | 31 (48.4) | 12 (18.8) | |
| SD | 10 (15.6) | 18 (28.1) | |
| PD | 5 (7.8) | 22 (34.4) | |
| Median PFS per IRF, months (95% CI) | 16.7 (15.4-21.6) | 3.5 (2.4-4.6) | |
| HR for PFS (95% CI) | 0.38 (0.25-0.58) | < .001 | |
| 3-year OS rate, % (95% CI) | 64.4 (50.7-75.2)† | 61.9 (47.3-73.6)‡ | |
| HR for OS (95% CI) | 0.75 (0.42-1.32) | .310 | |
| . | Brentuximab vedotin (n = 64) . | Physician’s choice (n = 64) . | P . |
|---|---|---|---|
| ORR4 per IRF, n (%) | 35 (54.7)∗ | 8 (12.5) | < .001 |
| Best response per IRF, n (%) | |||
| ORR (CR + PR) | 42 (65.6) | 13 (20.3) | < .001 |
| CR | 11 (17.2) | 1 (1.6) | .002 |
| PR | 31 (48.4) | 12 (18.8) | |
| SD | 10 (15.6) | 18 (28.1) | |
| PD | 5 (7.8) | 22 (34.4) | |
| Median PFS per IRF, months (95% CI) | 16.7 (15.4-21.6) | 3.5 (2.4-4.6) | |
| HR for PFS (95% CI) | 0.38 (0.25-0.58) | < .001 | |
| 3-year OS rate, % (95% CI) | 64.4 (50.7-75.2)† | 61.9 (47.3-73.6)‡ | |
| HR for OS (95% CI) | 0.75 (0.42-1.32) | .310 | |
PD indicates progressive disease; PR, partial response; and SD, stable disease.
Based on additional information provided to the IRF after the May 31, 2016 data cut-off, the IRF determined that 1 patient had not achieved ORR4 as was originally reported; the change in status was determined through a standard IRF adjudication process.
Median follow-up for OS in the brentuximab vedotin arm was 48.4 months.
Median follow-up for OS in the physician’s choice arm was 42.9 months.
Page 5102: under “Patient responses by baseline disease stage or extracutaneous involvement,” in the sentence that begins “The superiority of brentuximab vedotin over physician’s choice,” “stage IVB, 29% vs not available” should read “stage IVB, 29% vs not applicable.”
Page 5103: under “Peripheral neuropathy,” in the sentence that begins “Of the 44 patients with PN,” the percentage of the 9 patients permanently discontinuing brentuximab vedotin treatment should be 20%, not 14%.
Page 5104: under “Discussion,” in the second paragraph of the right column, in the sentence that begins “Limiting the assessment of OS according to assigned therapy,” the percentage of patients in the physician’s choice arm who received brentuximab vedotin as a subsequent treatment should be 69%, not 62%.
In supplemental Table 1, under “Overall (N=128),” in row “T1,” “5/13 (16)” should read “5/31 (16).” In supplemental Table 4, under “CR,” in row “T3,” “1(7)” should read “1(17).” The updated Supplement File 1 is included in the online version of this erratum. These errors do not impact the main findings or conclusions of the article.
